Research

Diranersen showed continued benefit in Alzheimer’s trial extension at 2 years

In an open-label extension, the twice-yearly 60-mg dose had a 1.09-point treatment difference on CDR-SB at 96 weeks.

Reported by 2 outlets Wednesday, November 18, 2026

Brain scan images on monitors in an MRI control room
Photo: Public domain, U.S. Navy Medicine

Diranersen, an investigational tau-targeting therapy, continued to show signs of slowing Alzheimer’s disease progression through 96 weeks, according to data from the phase II CELIA trial’s open-label extension. Lawren VandeVrede of the University of California San Francisco presented the findings at the Clinical Trials on Alzheimer’s Disease conference.

For participants taking 60 mg twice a year, the treatment difference on the Clinical Dementia Rating-Sum of Boxes score was 1.09 points at 96 weeks. The analysis compared 60 participants who received diranersen during the placebo-controlled phase and stayed on that dose with 115 people who switched from placebo to diranersen in the extension. VandeVrede said the treatment effect on this measure grew from 26% at week 76 to 38% at week 96.

Safety findings through week 96 were generally consistent with those from the placebo-controlled period. The most frequent adverse events included procedural pain, post-lumbar puncture syndrome, headache and confusional state. Laura Nisenbaum of the Alzheimer’s Drug Discovery Foundation said the findings need confirmation in a larger phase III trial. The extension is evaluating long-term safety, tolerability and durability of benefit.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.